Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), and the current treatment is centered on immunomodulatory and immunosuppressive medications. The ongoing COVID- 19 pandemic has raised concerns about the risk of infection in the general population and vulnerable patients such as those with MS. High-dose pulse steroid therapy and disease-modifying treatments (DMTs) modify the immune response, and concerns have been raised about the effects of these treatments may have on COVID-19 outcomes. MS and COVID-19 share immune system dysfunction, characterized by the inappropriate activity of major immune cells, such as T lymphocytes, and their imbalance in the level of released anti- and proinflammatory cytokines. Therefore, it is reasonable to draw some conclusions regarding the influence of MS medications on COVID-19 using data from international registries of COVID-19 among patients with multiple sclerosis (pwMS) and known pharmacology of DMTs. There is no single therapy that is successful in all cases of COVID-19 disease, and vaccination is the best strategy to combat the pandemic. Some DMTs may reduce the vaccine's effectiveness, although they may still give some protection against COVID-19 infection. A risk/benefit analysis should be performed before a decision is made about when to provide the vaccination and whether to defer the administration of the DMT dosage or not.